Dr. Reddy’s announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg & 20 mg, store-brand equivalent of Pe...
October 20 2020 - 3:44AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, along with its subsidiaries together referred to as “Dr.
Reddy’s”) today announced the re-launch of over-the-counter (OTC)
Famotidine Tablets USP, 10 mg and 20 mg, the store-brand
equivalents of Original Strength and Maximum Strength Pepcid AC®,
in the U.S. market, as approved by the U.S. Food and Drug
Administration (USFDA).
Dr. Reddy’s OTC Famotidine Tablets USP, 10 mg and 20 mg, are
acid reducers that prevent and relieve heartburn associated with
acid indigestion and sour stomach brought on by eating or drinking
certain food and beverages.
"We are pleased to continue to expand our OTC Antacid portfolio
for our customers and consumers,” says Marc Kikuchi, CEO, North
America Generics, Dr. Reddy’s Laboratories. “This launch will help
us fulfil an important therapy gap created in Antacids market due
to Ranitidine withdrawal.”
The Pepcid AC® brand and generic had U.S. sales of approximately
$211 million for the most recent twelve months ending in August
2020 according to IRi*.
Dr. Reddy’s OTC Famotidine Tablets USP, 10 mg and 20 mg, are
available in multiple pack sizes to allow consumers a variety of
purchasing options.
Pepcid AC® is a registered trademark of Johnson &
Johnson.
* IRi, Latest 52 weeks ending August 2020
RDY-1020-OTC
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues , and (vi) the susceptibility of our industry
and the markets addressed by our, and our customers’, products and
services to economic downturns as a result of natural disasters,
epidemics, pandemics or other widespread illness, including
coronavirus (or COVID-19), and (vii) other risks and uncertainties
identified in our public filings with the Securities and Exchange
Commission, including those listed under the "Risk Factors" and
"Forward-Looking Statements" sections of our Annual Report on Form
20-F for the year ended March 31, 2020. The company assumes no
obligation to update any information contained herein.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201020005522/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (PH:
+91-40-49002135)
MEDIA RELATIONS APARNA TEKURI aparnatekuri@drreddys.com
(PH: +91-40-49002446)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024